Literature DB >> 17250545

The definition and assessment of vitiligo: a consensus report of the Vitiligo European Task Force.

Alain Taïeb1, Mauro Picardo.   

Abstract

Vitiligo is the most common depigmenting disorder, which affects 0.5-1% of the worldwide population, causing disfigurement and serious disturbances in well being. There is a current lack of consensus in definition and methods of assessment of this disorder, which makes it generally impossible to compare the outcomes of different studies of the same treatment. This report summarizes the work carried out by the Vitiligo European Task Force to propose a consensus definition of the disease and to assess treatment outcomes using a system which combines analysis of extent, stage of disease (staging), and disease progression (spreading). In summary, extent is evaluated using the rule of 9. Staging is based on cutaneous and hair pigmentation in vitiligo patches, and the disease is staged 0-3 (revised version) on the largest macule in each body region, except hands and feet, which are assessed separately and globally as one unique area. Assessment of spreading is based on Wood's lamp examination of the same largest macule in each body area. Wood's lamp is useful for a combined assessment of staging and spreading in the same selected area. This study reports a workshop which validated the clinical use of the assessment form performed at several European University clinics, and showed an overall good concordance among panelists using the proposed scoring system. This system can be easily handled in clinical practice. However, variations between scorer profiles indicate a need for training to decrease interobserver variability. Further steps are envisaged, namely: (i) build a global index including staging and spreading for the initial assessment of vitiligo patients, usable as a guidance for therapeutic indications and prognosis, which could be interpreted as an equivalent of the TNM (tumor, node, metastasis) system for cancer; (ii) implement large-scale tests necessary for clinical trials (to check reproducibility and sensitivity); (iii) carry out studies of automated devices to assess extent more accurately; (iv) set up a teaching tool for scoring vitiligo, which could be posted on a website; and (v) set up an international conference on classifying, staging and scoring vitiligo, through the IFPCS Special Interest Group on Vitiligo.

Entities:  

Mesh:

Year:  2007        PMID: 17250545     DOI: 10.1111/j.1600-0749.2006.00355.x

Source DB:  PubMed          Journal:  Pigment Cell Res        ISSN: 0893-5785


  70 in total

1.  Heme oxygenase-1 expression protects melanocytes from stress-induced cell death: implications for vitiligo.

Authors:  Yasser E Elassiuty; Jared Klarquist; Jodi Speiser; Randa M Yousef; Abdelaziz A El Refaee; Nahla S Hunter; Olfat G Shaker; Mohan Gundeti; Ludmila Nieuweboer-Krobotova; I Caroline Le Poole
Journal:  Exp Dermatol       Date:  2011-03-22       Impact factor: 3.960

2.  Systemic analyses of immunophenotypes of peripheral T cells in non-segmental vitiligo: implication of defective natural killer T cells.

Authors:  Li Zhou; Kai Li; Yu-Ling Shi; Iltefat Hamzavi; Tian-Wen Gao; Marsha Henderson; Richard H Huggins; Oma Agbai; Bassel Mahmoud; Xiaofan Mi; Henry W Lim; Qing-Sheng Mi
Journal:  Pigment Cell Melanoma Res       Date:  2012-07-12       Impact factor: 4.693

Review 3.  [Vitiligo. Diagnosis, differential diagnosis, and current patient management].

Authors:  A Hartmann
Journal:  Hautarzt       Date:  2009-06       Impact factor: 0.751

4.  Influence of Pregnancy on Vitiligo Activity.

Authors:  Kirsten C Webb; Sarah Lyon; Beatrice Nardone; Dennis P West; Roopal V Kundu
Journal:  J Clin Aesthet Dermatol       Date:  2016-12-01

Review 5.  Vitiligo: Focus on Clinical Aspects, Immunopathogenesis, and Therapy.

Authors:  Katia Boniface; Julien Seneschal; Mauro Picardo; Alain Taïeb
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 8.667

6.  The association between a single nucleotide polymorphism rs11966200 in MHC region and clinical features of generalized vitiligo in Chinese Han population.

Authors:  Jin Tang; Jian Lan Liu; Cheng Zhang; Da Yan Hu; Su Min He; Xian Bo Zuo; Pei Guang Wang; Liang Dan Sun; Xue Jun Zhang; Sen Yang
Journal:  Mol Biol Rep       Date:  2013-03-21       Impact factor: 2.316

7.  Genome-wide association study for vitiligo identifies susceptibility loci at 6q27 and the MHC.

Authors:  Cheng Quan; Yun-Qing Ren; Lei-Hong Xiang; Liang-Dan Sun; Ai-E Xu; Xing-Hua Gao; Hong-Duo Chen; Xiong-Ming Pu; Ri-Na Wu; Chao-Zhao Liang; Jia-Bin Li; Tian-Wen Gao; Jian-Zhong Zhang; Xiu-Li Wang; Jun Wang; Rong-Ya Yang; Ling Liang; Jian-Bin Yu; Xian-Bo Zuo; Sheng-Quan Zhang; Shu-Mei Zhang; Gang Chen; Xiao-Dong Zheng; Pan Li; Jun Zhu; Yong-Wei Li; Xiao-Dong Wei; Wei-Song Hong; Ying Ye; Yong Zhang; Wei-Su Wu; Hui Cheng; Pu-Ling Dong; Da-Yan Hu; Yang Li; Min Li; Xin Zhang; Hua-Yang Tang; Xian-Fa Tang; Sheng-Xin Xu; Su-Min He; Yong-Mei Lv; Min Shen; Hong-Quan Jiang; Ying Wang; Kai Li; Xiao-Jing Kang; Yu-Qin Liu; Li Sun; Zhi-Fang Liu; Shao-Qiong Xie; Cheng-Yao Zhu; Qiang Xu; Jin-Ping Gao; Wen-Long Hu; Cheng Ni; Ting-Meng Pan; Yun Li; Sha Yao; Cai-Feng He; Yang-Sheng Liu; Ze-Ying Yu; Xian-Yong Yin; Feng-Yu Zhang; Sen Yang; Youwen Zhou; Xue-Jun Zhang
Journal:  Nat Genet       Date:  2010-06-06       Impact factor: 38.330

Review 8.  Polypodium leucotomos as an Adjunct Treatment of Pigmentary Disorders.

Authors:  Mark Nestor; Vivian Bucay; Valerie Callender; Joel L Cohen; Neil Sadick; Heidi Waldorf
Journal:  J Clin Aesthet Dermatol       Date:  2014-03

9.  [Treatment of vitiligo].

Authors:  M Meurer; M Schild
Journal:  Hautarzt       Date:  2016-03       Impact factor: 0.751

10.  No Association between Vitiligo and Obesity: A Case-Control Study.

Authors:  Federica Dragoni; Rossana Conti; Simone Cazzaniga; Roberta Colucci; Lisa Pisaneschi; Luigi Naldi; Silvia Moretti
Journal:  Med Princ Pract       Date:  2017-09-12       Impact factor: 1.927

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.